Nilotinib appears to help chronic myelogenous leukemia patients when standard care fails
HOUSTON -- The targeted agent nilotinib (AMN107) appears to offer striking benefits in patients with chronic myelogenous leukemia (CML) who are resistant to Gleevec, the standard therapy for this cancer, say researchers at The University of Texas M. D. Anderson Cancer Center. ...... Results of a 119-patient, phase I dose-escalation study, published June 15 in The New England Journal of Medicine,...